• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
No Result
View All Result
Home News Science

Human trials of world’s first HIV jab to begin

A protective injection is the 'holy grail' of AIDS research. Since the epidemic began almost four decades ago only four have been tested on patients - with none proving a success

Joe Mellor by Joe Mellor
2019-07-17 19:00
in Science
FacebookTwitterLinkedinEmailWhatsapp

Human trials of the world’s first HIV jab are to begin after the serum cleared the disease from monkeys.

The trials are to get underway after scientists developed a diluted version of their original vaccine – which was just as protective.

A protective injection is the ‘holy grail’ of AIDS research. Since the epidemic began almost four decades ago only four have been tested on patients – with none proving a success.

But the latest reported in two papers in the journal Science Translational Medicine is the most promising to date.

It uses a form of the common herpes virus cytomegalovirus – or CMV – that causes cold sores.

But it was ‘live-attenuated’ – meaning it was weakened so it does not cause serious disease, explained the microbiologists at Oregon Health and Science University.

Examples include the MMR (measles, mumps, and rubella) and varicella (chickenpox) vaccines.

RelatedPosts

Plastic food packaging can contain hundreds of chemicals and serious damage to humans is revealed

Brexit: Britain can’t access vast EU science funding due to ongoing tensions

Professor Brian Cox’s comment about a sanctioned Russian superyacht is brilliant

BBC’s Dan Walker called out a Daily Mail blooper and it was epic

It still managed to wipe out SIV (simian immunodeficiency virus) – the monkey version of HIV (human immunodeficiency virus) – in 16 of 27 immunised rhesus macaques.

The 59 per cent success rate is similar to results achieved using the stronger ‘non-attenuated’ form.

It was also long-lasting. Nine out of 12 monkeys given a second dose of SIV could still fight it off – three years later.

Co-corresponding author Professor Klaus Fruh said: “This research, using rhesus CMV, provides potentially important insights into the design of a human CMV-based HIV vaccine.

“We significantly attenuated CMV and still got the same type of immune responses as with the wild version of this vaccine.”

A less powerful vaccine is the key to it being potentially viable for humans due to safety concerns.

People are often infected with CMV without any trouble but it can wreak havoc on those with weakened immune systems – such as organ transplant patients.

It’s also dangerous for pregnant women as it can cause congenital defects such as cerebral palsy, deafness and developmental delay.

Prof Louis Picker, corresponding author on both studies, said: “These papers are important because they recapitulate the previously reported unique CMV vector efficacy with a genetically modified vector that is highly attenuated and therefore potentially safer for clinical use.

“In addition, this new work demonstrates most vaccinated rhesus macaques that are protected against SIV can also be protected against a second challenge years after initial vaccination.

“This is a level of durability that would be very important for a human HIV vaccine.”

It paves the way for more broadly usable – but still potent – CMV-based vaccines that could be administered to individuals with weak immune systems.

It could also prevent HIV in vulnerable members of society, said Prof Picker.

The CMV vaccine has been licensed by San Francisco based Vir Biotechnology – and has been backed by the Bill & Melinda Gates Foundation.

It is already planning to lead a clinical trial with a human version of the therapy.

Vaccines with CMV have emerged as a potential treatment for diseases like HIV and have shown promise in several primate studies, said Prof Picker.

But the virus can cause severe symptoms in humans with weakened immune systems – which has limited the therapeutic potential.

So the researchers tackled this issue by engineering the vaccine to provoke responses from the intrinsic immune system – which specifically targets viruses.

By taking out a protein called pp71 it fired immune cells into action without spreading past the injection site – or to unexposed animals.

The second study found the new jab spread up to 1,000 times less than unmodified CMV in vaccinated rhesus monkeys – while still generating potent responses from the T cells that had been primed to attack HIV.

Vaccines using a similar technique are also being developed by the same team to combat tuberculosis.

https://www.thelondoneconomic.com/lifestyle/health/hiv-breakthrough-the-aids-causing-virus-has-been-wiped-out-for-first-time-in-living-animals/02/07/

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Watch: Riot police enter oligarch’s mansion making mockery of Tory plans to house refugees in Russia owned homes

In Pics – Hilarious expressions on dogs’ faces as they try to catch a treat

Cocktail Recipe: Colonsay Bees Knees

Set For Life Results LIVE for Thursday 8 July 2021 Tonight’s winning numbers

Mum & daughter’s lives transformed by beautiful dog they helped save from hellhole

Mass confusion as racists accidentally vote for closer ties to Middle East

Beer of the Week: Lost and Grounded Running With Sceptres

Set For Life Results for Thursday 30 December 2021 Tonight’s winning numbers

Business owner fights back tears as she discusses impact of Brexit uncertainty

Johnson ‘in charge’ of Iran situation despite holiday, Raab claims

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.